WebLog Journal of Medical Sciences

Review Article
Published: 18 May, 2026

Diabetic Neuropathy: Comprehensive Overview of Epidemiology, Classification, Pathophysiology, Clinical Features, and Management

*Iwuamadi Ojiugo C, Obasi Miriam, Oparaocha Divine Gift, Okafor Onyeka, Alozie Okezie, Nwadike Constance and Johnkennedy Nnodim**

Department of Medical Laboratory Science, Imo State University, Owerri, Nigeria

Abstract

Diabetic neuropathy (DN) is a prevalent and debilitating chronic consequence of diabetes mellitus, impacting over 50% of patients with long-standing illness. It includes a wide range of illnesses that affect peripheral and autonomic nerves, which can cause loss of sensation, neuropathic pain, autonomic dysfunction, and a higher risk of foot ulcers and amputations. Even though diabetes treatment has gotten better, DN is still not diagnosed or treated well enough, mostly because its aetiology is complicated and its clinical presentation might change. This narrative review offers a comprehensive synthesis of the epidemiology, categorisation, pathophysiological causes, clinical manifestations, diagnostic methodologies, and contemporary therapy techniques for diabetic neuropathy. The multifaceted character of nerve injury is highlighted, encompassing metabolic, vascular, inflammatory, and neurotrophic aspects, alongside growing understandings of mitochondrial malfunction and small-fiber disease. Current therapeutic treatments, including preventative measures, symptomatic pain management, and treatment of autonomic problems, are critically evaluated alongside emerging disease-modifying strategies. Finally, important gaps in diagnosis and treatment are pointed out, showing how important it is to have tools for early detection, personalised treatment plans, and effective neuroprotective therapies to lessen the effects of diabetic neuropathy.

Keywords: Diabetic Neuropathy; Diabetes Mellitus; Peripheral Neuropathy; Autonomic Neuropathy; Neuropathic Pain; Metabolic Problems

OPEN ACCESS

Correspondence:
Johnkennedy Nnodim, Department of Medical Laboratory Science, Imo State University, Owerri, Nigeria, Tel: 08181366290; E-mail: johnkennedy23@yahoo.com

Received Date: *28 Apr 2026*
Accepted Date: *15 May 2026*
Published Date: *18 May 2026*

Citation:
Iwuamadi Ojiugo C, Miriam O, Divine Gift O, Onyeka O, Okezie A, Constance N, et al. Diabetic Neuropathy: Comprehensive Overview of Epidemiology, Classification, Pathophysiology, Clinical Features, and Management. WebLog J Med Sci. wjms.2026.e1806. https://doi.org/10.5281/zenodo.20337050

Introduction

Diabetes mellitus (DM) is becoming a bigger problem for public health around the world, with rates of the disease rising in both developed and developing countries. Diabetes has long-term repercussions that make people sick, kill them, and cost a lot of money to treat. Diabetic neuropathy (DN) is one of the most prevalent and debilitating of these complications. Diabetic neuropathy (DN) affects about 50% of people who have had diabetes for a long time. It is one of the main causes of sensory loss, chronic neuropathic pain, foot ulcers, and lower-limb amputations that aren't caused by an injury [1].

Diabetic neuropathy is not a singular condition but a diverse collection of illnesses affecting peripheral somatic and autonomic nerves. The most common type, distal symmetric polyneuropathy (DSPN), usually shows up in a "stocking-glove" pattern that depends on the length of the nerve and gets worse slowly over time. Other forms of neuropathy include autonomic neuropathy, localised and multifocal neuropathies, and radiculoplexus syndromes. Each of them has its own clinical meaning and prognostic value. The variety of clinical manifestations frequently hinders diagnosis and postpones prompt intervention [2].

The pathophysiology of diabetic nephropathy (DN) is intricate and involves multiple factors. Chronic hyperglycemia triggers a series of metabolic disruptions, encompassing the activation of the polyol pathway, the buildup of advanced glycation end-products, oxidative stress, and mitochondrial dysfunction. These metabolic injuries, exacerbated by microvascular ischaemia, neuroinflammation, and diminished neurotrophic support, lead to progressive nerve fibre destruction. Small-fiber neuropathy may present early in the illness trajectory, exhibiting as pain and autonomic dysfunction prior to the identification of abnormalities in standard nerve conduction testing.

Even though diabetic neuropathy is very common and has a big effect on health, most of the time it is only treated with symptom relief. Tight glycaemic control and lowering the risk of heart disease are the most important parts of prevention. On the other hand, pharmacologic therapy for severe diabetic neuropathy is mostly about relieving symptoms rather than changing the illness. New treatments that focus on oxidative stress, inflammation, and nerve regeneration show promise, but they haven't yet become routinely effective in clinical settings [3].

This narrative review seeks to deliver a thorough and therapeutically pertinent synthesis of the existing knowledge regarding diabetic neuropathy. The review emphasises current issues and delineates future paths essential for enhancing outcomes for individuals with diabetes by synthesising epidemiological data, molecular insights, diagnostic methodologies, and management techniques.

Epidemiology and Clinical Impact of Diabetic Neuropathy

Diabetic neuropathy (DN) is one of the most common and serious long-term problems that can happen with diabetes mellitus, yet it is not always recognised in everyday medical practice. The frequency of this condition varies significantly among research, indicating disparities in population characteristics, diagnostic criteria, and the length of diabetes. There is, however, a lot of consensus that DN affects a large number of people with diabetes and is a major cause of diabetes-related illness around the world [4].

Epidemiological studies indicate that distal symmetric polyneuropathy (DSPN), the predominant variant of diabetic neuropathy (DN), may affect roughly 10–15% of persons at the time of type 2 diabetes diagnosis, with prevalence increasing progressively as illness duration extends. In individuals with chronic diabetes, especially those with a duration beyond 10 years, the prevalence may surpass 50%. These numbers show an essential clinical fact: diabetic neuropathy is not a rare or late complication, but an expected result in many patients if metabolic management and risk variables are not properly managed [5].

The real impact of DN on daily living and quality of life is more important than just the number of people who have it. A lot of patients have long-term sensory problems like numbness, tingling, or searing sensation, which usually happen in the feet and lower limbs. Diabetic neuropathy that hurts is linked to sleep problems, less mobility, mental anguish, and less work productivity. Anxiety and depressed symptoms are commonly observed, indicative of the chronic and intrusive characteristics of neuropathic pain [6].

The clinical ramifications of sensory loss surpass mere discomfort. A considerable rise in the likelihood of foot injury occurs with the loss of protective feeling, which may remain undetected until infection or ulceration ensues. Diabetic neuropathy is a significant risk factor for diabetic foot ulcers and non-traumatic lower-limb amputations. These difficulties have significant human consequences for patients and families, as well as considerable economic repercussions for healthcare systems due to extended hospital stays, surgical procedures, and lengthy rehabilitation [7].

Autonomic neuropathy exacerbates the illness burden and is frequently neglected due to its modest or nonspecific manifestations. Cardiovascular autonomic dysfunction may present as resting tachycardia, orthostatic hypotension, or silent myocardial ischaemia, all of which correlate with elevated mortality rates. Involvement of the gastrointestinal and genitourinary systems can severely impair nutrition, glycaemic management, and psychological health, highlighting the systemic characteristics of diabetic neuropathy [8].

The burden of diabetic neuropathy is not evenly distributed, which is important to note. People who have poor glycaemic control, have had diabetes for a long time, have high blood pressure or high cholesterol, or live an unhealthy lifestyle (such smoking) are at a higher risk. In low- and middle-income contexts, restricted access to regular screening, patient education, and specialised care exacerbates the issue, resulting in delayed presentation and more severe sequelae [9].

These observations underscore that diabetic neuropathy is not solely a neurological diagnosis but a disorder with extensive clinical and societal ramifications. Understanding its epidemiology and impact underscores the necessity for early screening, preventive measures, and holistic therapy focused on alleviating symptoms while maintaining functionality and quality of life.

Diabetic Neuropathy: Classification and Phenotypic Spectrum

iabetic neuropathy consists of various clinical symptoms instead than a singular, homogenous condition. Recognising this variability is crucial in daily treatment, as the neuropathy pattern frequently dictates prognosis, directs investigations, and affects therapeutic choices. Distal symmetric polyneuropathy (DSPN) is the most prevalent form of the disease, but there are other clinically important forms as well.

Diabetic neuropathy is mostly caused by DSPN, which usually happens slowly over a number of years. It is a length-dependent neuropathy that mostly affects the feet and then moves up the body, creating the distinctive "stocking-glove" distribution. People with this condition often say they feel numb, tingly, or burning, and these feelings are worse at night.

A typical clinical situation is a middle-aged or older patient with chronic type 2 diabetes who exhibits painless foot numbness and subsequently develops foot ulcers due to diminished protective feeling. As proprioception and vibration sensation decrease, instability in gait and falls may ensue, especially among elderly persons [10].

Painful diabetic neuropathy is a troubling part of DSPN that commonly sends people to the doctor. People often say that the pain feels like it is scorching, electric, or stabbing, and it can happen even when there are no clear neurological problems on a normal checkup. Clinically, these individuals often experience intense nocturnal discomfort that disrupts sleep and daily activities. Patients and doctors often get frustrated when the severity of symptoms doesn't match the modest findings on tests. This shows how important it is to recognise small-fiber involvement early [11].

Autonomic neuropathy indicates the involvement of autonomic nerve fibres and may impact several organ systems. Its appearance is frequently modest and easily noticed until deliberately pursued.

A patient with chronic diabetes may report dizziness upon standing, indicative of orthostatic hypotension, or may exhibit inexplicable resting tachycardia. Some individuals may experience gastroparesis, resulting in unstable glycaemic management, or

genitourinary manifestations, including erectile dysfunction or bladder dysfunction. Cardiovascular autonomic neuropathy is especially alarming due to its association with silent myocardial ischaemia and elevated mortality [12].

Focal and multifocal neuropathies are infrequent yet clinically significant due to their abrupt onset and frequently striking manifestation. These encompass cranial nerve palsies, mononeuropathies including median nerve entrapment, and lumbosacral radiculoplexus neuropathy (diabetic amyotrophy).

A common instance is an elderly diabetic patient who experiences acute diplopia resulting from a third cranial nerve palsy, frequently accompanied by pupillary sparing. These neuropathies, while concerning, are typically self-limiting and may resolve within weeks to months, if alternative aetiologies are ruled out [13].

Clinical Significance of Phenotyping

ifferentiating these traits transcends mere academic pursuit. various types of diabetic neuropathy come with various dangers, ways to diagnose them, and ways to treat them. While DSPN focusses on preventing foot problems and lowering long-term risks, painful neuropathy needs particular symptom control, and autonomic neuropathy needs organ-specific testing and monitoring. Recognising the phenotypic spectrum enables physicians to transcend a uniform approach and deliver care that is more congruent with the specific needs of each patient.

Pathophysiological mechanisms of diabetic neuropathy

he emergence of diabetic neuropathy is most accurately characterised not as the consequence of a singular injury, but as the aggregate impact of various interrelated processes occurring over time. In clinical terms, prolonged exposure to hyperglycemia predisposes individuals to progressive nerve injury, whereas vascular, inflammatory, and metabolic variables dictate the rate and severity of the disease. This "multi-hit" model elucidates the varied presentation of diabetic neuropathy and the absence of a uniformly successful therapy [14].

Metabolic Damage with Long-Term High Blood Sugar

hronic hyperglycemia is still the leading cause of nerve injury in diabetes. Too much glucose inside neurones and Schwann cells is sent down other metabolic pathways that neural tissue doesn't like very much. The polyol route is one of these ways. In this pathway, glucose is turned into sorbitol, which causes osmotic stress and more oxidative damage in nerve cells [15].

From a therapeutic standpoint, this metabolic stress progressively diminishes neuronal conduction and axonal integrity. Patients may first experience periodic tingling or burning sensations, especially at night, far before any objective abnormalities are identified in nerve conduction testing. This elucidates the challenges in confirming early neuropathy with standard diagnostic methods despite its clinical presentation.

Oxidative Stress and Mitochondrial Dysfunction

xidative stress is a key factor in turning high blood sugar levels into damage to the structure of nerves. Too much reactive oxygen species can damage antioxidant defences, which can cause problems with mitochondria and make it harder for neurones to make energy [16]. Clinically, this bioenergetic failure disproportionately impacts lengthy peripheral nerves, which possess elevated metabolic requirements. This sensitivity that depends on length is why symptoms usually start in the feet and move up the body over time. It also explains why better glycaemic control later in the disease may slow down the disease's course but not reverse neuropathy that has already happened.

Insufficiency of the Microvasculature

Nerves rely heavily on a sufficient microvascular supply. In diabetes, alterations in the vasa nervorum's structure, such as thickening of the basement membrane and constriction of the capillaries, diminish endoneurial blood flow and oxygen transport. The ischaemia that follows makes metabolic damage worse and speeds up the breakdown of nerve fibres [17].

In reality, this vascular contribution elucidates the accelerated progression of diabetic neuropathy in patients with concurrent hypertension, dyslipidaemia, or a history of smoking. It also shows how important it is to manage all of a person's cardiovascular risks in order to prevent neuropathy, not only glycaemic control.

Neuroinflammation and Pain Sensitivity

Low-grade chronic inflammation has become a significant factor in nerve injury and neuropathic pain. Pro-inflammatory cytokines, including tumour necrosis factor-α and interleukin-6, exacerbate neuronal damage and elevate pain signals in both the peripheral and central nervous systems [18].

In a clinical setting, this inflammatory environment is especially pertinent in painful diabetic neuropathy, where sensations can be intense despite the preservation of large-fibre function. Patients frequently report heightened pain reactions to modest stimuli, indicating peripheral and central sensitisation rather than mere anatomical nerve loss.

Neurotrophic Support and Nerve Repair That Doesn't Work

Diabetes also disrupts the normal processes of neurone maintenance and regeneration. The diminished availability of neurotrophic factors, coupled with compromised axonal transport, constrains the potential for nerve healing post-injury [19].

This diminished regeneration capacity is clinically manifested in the protracted and frequently partial recovery observed following localised neuropathies or nerve compression syndromes in individuals with diabetes. This elucidates the persistent research focus on experimental medicines designed to promote neurone development.

Clinical Consequences of Mechanistic Understanding

These mechanisms collectively elucidate the challenges in treating established diabetic neuropathy. When symptoms are visible in a therapeutic setting, many harmful processes are already at work. This shows how important it is to find problems early, change risk factors quickly, and address symptoms quickly.

Clinicians can better explain the disease to patients, set realistic expectations, and take a more holistic approach that targets metabolic management, vascular health, and pain modulation at the same time if they understand the pathophysiology in clinically meaningful terms [5].

Clinical Characteristics and Diagnostic Methodologies

Diabetic neuropathy manifests with a diverse array of symptoms

that can develop progressively, complicating early identification. Sensory, motor, or autonomic nerves may be involved, and sensory symptoms are the most common. Patients seldom employ scientific terminology in ordinary treatment; rather, they articulate sensations of numbness, burning, tingling, or a "pins-and-needles" feeling, especially in the feet and exacerbated at night [20].

Sensory complaints typically predominate in the initial stages of the disease. Patients may report excruciating burning sensations or, alternatively, total numbness resulting in unnoticed injuries. A common situation involves a patient who arrives late with a foot ulcer and subsequently discovers the loss of protecting feeling. Small-fiber involvement frequently presents initially, resulting in pain and heat sensory loss despite normal regular nerve conduction testing [21].

Motor involvement is infrequent and typically manifests in advanced disease or specific neuropathies. When it is, it can produce weakening in the distal muscles, muscle atrophy, or unstable walking. In patients with unexplained orthostatic dizziness, resting tachycardia, gastrointestinal dysmotility, or genitourinary dysfunction, particularly those with long-standing diabetes [12], autonomic involvement should be suspected.

The clinical examination is still the most important part of making a diagnosis. Basic bedside instruments are frequently adequate for the identification of clinically relevant neuropathy. The 10-g monofilament test is a common way to check for loss of protective feeling and forecast the likelihood of ulcers. Using a 128-Hz tuning fork for vibration testing and checking ankle reflexes makes it even easier to find large-fiber dysfunction [16].

Testing for pinprick and temperature sensitivity is very helpful for finding small-fiber neuropathy, which can cause pain even when there are no obvious large-fiber problems. These bedside tests are cheap, rapid, and especially useful in places with few resources.

Tests for diagnosis

or most people, diabetic neuropathy is diagnosed based on their symptoms. Further investigations are conducted for uncommon presentations, fast development, or diagnostic ambiguity. Nerve conduction investigations are helpful for verifying large-fiber involvement and ruling out other possible causes, but they may be normal in cases with early or painful neuropathy [22].

For suspected small-fiber neuropathy, skin biopsy evaluating intraepidermal nerve fibre density remains the gold standard, albeit its accessibility is restricted. When autonomic dysfunction is suspected, autonomic testing, such as heart rate variability and tilt-table testing, may be necessary [23].

Practical Diagnostic Method

A practical strategy entails annual screening of all diabetic patients using medical history and bedside testing, with additional investigations directed by symptomatology and clinical context. It is important to remember that the absence of aberrant test results does not mean that the patient-reported symptoms, especially pain, are not real. Pain is often a sign of early small-fiber involvement.

Early detection enables prompt education, foot care, and symptom management, aiding in the prevention of severe problems such as ulceration and falls.

Strategies for Management

To effectively manage diabetic neuropathy (DN), a comprehensive strategy focussing on both prevention and symptom alleviation is essential. Present tactics prioritise glycaemic management as a fundamental aspect, especially in type 1 diabetes, where stringent regulation markedly diminishes the occurrence and advancement of neuropathy [24].

Furthermore, it is imperative to tackle modifiable risk factors, including smoking cessation, hypertension, dyslipidaemia, and obesity, to decelerate disease progression and alleviate vascular contributions to nerve injury [25].

Symptomatic treatment mainly aims to relieve neuropathic pain, utilising first-line pharmacotherapies such as serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine), gabapentinoids (e.g., pregabalin), and tricyclic antidepressants. Capsaicin patches and other topical medications can help with localised pain, especially in cases of focal pain syndromes. For autonomic neuropathy, organ-specific treatments are used. For example, prazosin or midodrine are used for orthostatic hypotension, prokinetics are used for gastroparesis, and phosphodiesterase-5 inhibitors are used for erectile dysfunction.

New treatments including nerve growth factors, antioxidants, and drugs that target advanced glycation end-products show promise for changing the course of diseases, although they are still mostly experimental. Progress in regenerative medicine, such as stem cell therapy and gene editing, is still in its infancy, but it could change the way DN is treated. A multidisciplinary strategy that focusses on teaching patients, taking care of their feet, and changing their way of life is still the best way to lower the risk of problems including foot ulcers and amputations [26].

Conclusion

Diabetic neuropathy is still a common and debilitating consequence of diabetes mellitus that has a big effect on the quality of life of patients and healthcare systems around the world. Although current therapy strategies—focused on glycaemic control, risk factor modification, symptom relief, and patient education—have shown efficacy in decreasing morbidity, substantial deficiencies remain. Notably, early identification of short fibre neuropathy and the advancement of disease-modifying treatments are essential unmet requirements. Future progress depends on combining mechanistic knowledge with new ways to diagnose and treat diseases, with a focus on personalised and regenerative methods. A concerted, interdisciplinary effort is essential to alleviate the burden of DN and improve patient-centered care.

References

1. Soroku Y, Yamagishi S and Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms. Diabetes Research and Clinical Practice, 2007, 77(Suppl. 1), S184–S189.
2. Vincent A.M, Callaghan B.C, Smith A.L and Feldman E.L. Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nature Reviews Neurology, 2011, 7(10), pp.573–583.
3. Dubský M, Selvarajah D and Tesfaye S. Diabetic peripheral neuropathy: new diagnostics and therapeutic approaches. Drugs, 2025, 85(2), 125–142.
4. Ziegler D, Strom A, Lobmann R and Reiners K. Update on diagnosis and treatment of diabetic neuropathy. *The Lancet Diabetes & Endocrinology*, 2022, 10(7), .485–496.
5. Armstrong D.G, Boulton A.J.M and Bus S.A. Diabetic foot ulcers and

their recurrence. The New England Journal of Medicine, 2023, 376(24), 2367–2375.

6. Vinik A.I, Nevoret M.L, Casellini C and Parson H. Diabetic neuropathy. Endocrinology and Metabolism Clinics of North America, 2013, 42(4), pp.747–787.
7. Atmaca A, Yıldırım A, Arslan M and Demir S. Expert perspectives on the pathophysiology and clinical management of diabetic peripheral neuropathy. *Frontiers in Endocrinology*, 2024, 15, 1380929.
8. Boulton A.J.M, Vinik A.I, Arezzo J.C, Bril V, Feldman E.L, Freeman R, Malik R.A, Maser R.E, Sosenko J.M and Ziegler D. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care, 2005, 28(4), 956–962.
9. Tao Y, Liu X, Zhang L and Wang Y. Prevalence and risk factors of painful diabetic neuropathy: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2025, 204, 110847.
10. Cameron N.E, Eaton S.E, Cotter M.A and Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 2001, 44(11), 1973–1988.
11. Elafros M.A and Callaghan B.C. Diabetic neuropathies. Continuum (Minneapolis, Minn.), 2023, 29(5), 1401–1417.
12. Jang H.N, Kim Y.J and Lee S.H. Pharmacological and non-pharmacological treatments for painful diabetic peripheral neuropathy. Diabetes & Metabolism Journal, 2023, 47(4), 523–539.
13. Vlassara H and Uribarri J. Glyoxalase and diabetic complications. Diabetes Care, 2014, 37(4), 935–938.
14. Strand N, Anderson M.A, Attanti S, Liang C, Shapiro R.E and McCarberg B.H. Diabetic neuropathy: Pathophysiology review. Current Pain and Headache Reports, 2024, 28(6), 481–490.
15. Ma J, Yu H, Liu J, Chen Y, Wang Q and Xiang L. Curcumin promote nerve regeneration and functional recovery after sciatic nerve crush injury in diabetic rats. Neuroscience Letters, 2016, 610, 139–143.
16. Sloan G, Shillo P, Selvarajah D and Tesfaye S. A new look at painful diabetic neuropathy. Diabetes Research and Clinical Practice, 2018, 144, 177–191.
17. Tesfaye S, Selvarajah DGandhi R, Greig M, Shillo P, Fang F and Wilkinson I.D. Diabetic peripheral neuropathy: Advances in pathogenesis and management. *Diabetes Research and Clinical Practice*, 2023, 197, 110562.
18. Vashishta P, Bansal V and KalraS. Emerging paradigms in diabetic neuropathy: Epidemiology and clinical impact. Neuroscience Reviews, 2025, 36(1), 45–63.
19. World Health Organization. Global report on diabetes. Geneva: WHO. 2016.
20. Yang Y, Zhao B, Wang Y, Liu Z and Zhang X. Diabetic neuropathy: cutting-edge research and future directions. Signal Transduction and Targeted Therapy, 2025, 10, 132.
21. Zhu J, Hu Z, Luo Y, Chen Y and Wang Q. Diabetic peripheral neuropathy: pathogenetic mechanisms and therapeutic strategies. Frontiers in Endocrinology, 2024, 14, 1265372.
22. Callaghan B.C, Gallagher G, Fridman V and Feldman E.L. Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology, 2020, 19(6), pp.521–534.
23. Tesfaye S and Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes/Metabolism Research and Reviews, 2020, 36(S1), e3250.
24. Mallick-Searle T and Adler J.A. Update on treating painful diabetic peripheral neuropathy: Current U.S. guideline-based recommendations. *Journal of Pain Research*, 2024, 17,1005–1028.
25. Pop-Busui R, Boulton A.J.M, Feldman E.L, Bril V, Freeman R, Malik R.A, Sosenko J.M and Ziegler D. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care, 2022, 45(1),136–154.
26. Sayed D, Abd-Elsayed A, Mounir-Said S and Deer T. A systematic guideline on painful diabetic neuropathy by the American Society of Pain and Neuroscience. *Journal of Pain Research*, 2024, 17, 1421–1443.